Catalyst Wire Dossier Catalyst Wire Dossier

Sofosbuvir/velpatasvir/GS-9857 fixed-dose combination

sofosbuvir/velpatasvir/GS-9857 · Gilead Sciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sofosbuvir/velpatasvir/GS-9857 fixed-dose combination, covering 2020-09-02 to 2020-09-02. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol [Phase 1]

See pricing